Gates Foundation and Hetero Labs Partner to Revolutionize HIV Prevention with Injectable Drug.
The Gates Foundation and Hetero Labs have collaborated to produce a generic version of lenacapavir, the world's first injectable HIV prevention drug. This breakthrough aims to reduce costs and improve access to HIV prevention, particularly in low- and middle-income countries.
Lenacapavir offers a significant advancement in HIV prevention, requiring only two injections per year compared to daily oral medication. The partnership is expected to lower the annual cost per patient to around $40, making it more accessible to those in need.
This initiative marks a crucial step towards sustainable and affordable HIV prevention solutions, addressing adherence challenges and supply chain issues.
Plus234Feed summary based on reporting from This Day. Read the original report below.
Read full article
Continue on This Day
Get the week in one email
Top stories, NPFL results, the naira — every Friday morning. Free, one email a week.
Related Stories
Nigeria Secures Affordable HIV Prevention Drug Lenacapavir at UNGA80
NBRDA Partners for Local Production of HIV Drugs in Nigeria
Nigeria Enhances HIV Response Through Technology and Human-Centered Care
PMTCT Prevents 22,000 New HIV Infections Annually in Nigeria - Dr. Tim Efuntoye Reveals Impact
Nigeria's Water Minister Urges Ecosystem Protection for Rivers
Colonel Peter Kolawole Obasa, NYSC DG, Dies at 88
Get Plus234Feed on messaging apps
Same headlines, delivered where you already scroll.
